Recent 8-K filings for SYRE

• May 5, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029

  Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).

• April 16, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share

  Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.

• April 13, 2026, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission

  SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.

• April 13, 2026, 7:59 PM ET other material materiality 0.70 positive item 2.02item 8.01

  Spyre reports preliminary $741M cash; suspends ATM offering

  Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.

• January 12, 2026, 6:59 PM ET leadership materiality 0.70 positive item 7.01item 9.01

  Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026

  Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.

• November 4, 2025, 6:59 PM ET other material materiality 0.85 positive item 2.02item 7.01item 8.01item 9.01

  Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M

  SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.

• October 15, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 9.01

  Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50

  Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.

• August 5, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive

  Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.

• June 17, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated

  SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025

  Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.

• March 6, 2025, 6:59 PM ET other material materiality 0.75 negative item 4.01item 9.01

  Spyre dismisses PwC as auditor, appoints KPMG; discloses material weakness in controls

  PwC dismissed as auditor effective Feb 28, 2025; KPMG appointed as new independent auditor for FY2025.

• February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025

  Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.

• January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02item 8.01item 9.01

  Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028

  Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.

• November 19, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50

  Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.

• November 18, 2024, 6:59 PM ET other material materiality 0.85 negative item 4.02item 8.01

  Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls

  Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.

• November 12, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing

  SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.

• November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end

  Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.

• October 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 8.01item 9.01

  Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M

  First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end

  Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

11 positive 2 negative 13 neutral

source · SYRE on sec.gov